Royalty Pharma (RPRX) EVP sells 13,684 shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported an open-market sale of 13,684 Class A Ordinary Shares on May 14, 2026 at a weighted average price of $53.0647 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026.

Following the sale, Urist directly holds 31,881 Class A Ordinary Shares and indirectly holds 19,020 shares through an IRA. The sale price reflected multiple transactions within a range of $52.88 to $53.25 per share.

Insider Trade Summary 10b5-1

Net Seller: 13,684 shares ($726,137)

Net Sell 2 txns

Insider Urist Marshall

Role EVP, Research & Investments

Sold 13,684 shs ($726K)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	13,684	$53.0647	$726K
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 31,881 shares (Direct, null); Class A Ordinary Shares — 19,020 shares (Indirect, By IRA)

Footnotes (1)

All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.88 to $53.25 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 13,684 shares Weighted average sale price: $53.0647 per share Price range: $52.88–$53.25 per share +3 more

6 metrics

Shares sold 13,684 shares Open-market sale on May 14, 2026

Weighted average sale price $53.0647 per share Class A Ordinary Shares, May 14, 2026

Price range $52.88–$53.25 per share Range of individual sale transactions

Direct holdings after sale 31,881 shares Class A Ordinary Shares held directly after transaction

Indirect holdings after sale 19,020 shares Held indirectly through IRA

Trading plan adoption date February 12, 2026 Rule 10b5-1 plan governing reported sale

Key Terms

Rule 10b5-1 plan, weighted average price, Class A Ordinary Shares, open-market sale, +1 more

5 terms

Rule 10b5-1 plan regulatory

"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Class A Ordinary Shares financial

"security_title: Class A Ordinary Shares"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

IRA financial

"nature_of_ownership: By IRA"

An individual retirement account (IRA) is a savings account designed to help people put aside money for their retirement, often with tax advantages that encourage long-term savings. It matters to investors because it can grow over time, providing financial security later in life, and offers benefits that can reduce current taxes or allow investments to compound more effectively.

Form 4 Insider Transactions: What Each Field Means →

05/15/2026 - 04:38 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Urist Marshall

(Last)

(First)

(Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Research & Investments

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Ordinary Shares	05/14/2026		S⁽¹⁾		13,684	D	$53.0647⁽²⁾	31,881	D
Class A Ordinary Shares								19,020	I	By IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.88 to $53.25 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Royalty Pharma (RPRX) disclose for Marshall Urist?

Marshall Urist reported selling 13,684 Royalty Pharma Class A Ordinary Shares. The sale occurred on May 14, 2026, as an open-market transaction and was executed under a pre-arranged Rule 10b5-1 trading plan adopted earlier in February 2026.

At what price did Marshall Urist sell Royalty Pharma (RPRX) shares?

The reported sale used a weighted average price of $53.0647 per share. Individual trades occurred in multiple transactions, with prices ranging from $52.88 to $53.25 per share, according to the Form 4 disclosure and its accompanying pricing footnote.

How many Royalty Pharma (RPRX) shares does Marshall Urist hold after the transaction?

After the reported sale, Marshall Urist directly holds 31,881 Class A Ordinary Shares. In addition, he indirectly holds 19,020 Royalty Pharma shares through an IRA account, providing a combined picture of his direct and indirect ownership positions.

Was Marshall Urist’s Royalty Pharma (RPRX) sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states all reported transactions were effected under a Rule 10b5-1 trading plan. This plan was adopted by Marshall Urist on February 12, 2026, indicating the sale was pre-arranged rather than an ad hoc market decision.

What type of security did Marshall Urist trade in Royalty Pharma (RPRX)?

The transaction involved Royalty Pharma Class A Ordinary Shares. The Form 4 identifies the security title explicitly and reports both the number of shares sold and the resulting direct and indirect share balances after the May 14, 2026 transaction.